ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,246Medicare Part D Prescriptions Filled, Including Refills

Rank: 66 out of 1290

$506K Total Retail Price of All Prescriptions

Rank: 196 out of 1290

297 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
93% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

2% of this provider’s 9,714 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

31% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $94 among peers.

Prescriptions per Patient

35 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
SIMVASTATIN 480 460 1 1
RANITIDINE HCL 463 424 2 49
AMLODIPINE BESYLATE 409 407 3 3
METFORMIN HCL 387 349 4 10
LISINOPRIL 305 274 5 5
CRESTOR 279 254 6 17
LOVAZA 237 212 7 131
ISOSORBIDE MONONITRATE ER 231 227 8 58
LOSARTAN POTASSIUM 227 219 9 19
PRAVASTATIN SODIUM 212 201 10 42
LEVOTHYROXINE SODIUM 180 165 11 4
FUROSEMIDE 167 164 12 9
GABAPENTIN 165 162 13 8
ATENOLOL 164 155 14 18
DIOVAN 163 150 15 53
TRAMADOL HCL 152 142 16 25
LOVASTATIN 149 140 17 45
CARVEDILOL 147 143 18 12
DONEPEZIL HCL 144 144 19 13
OMEPRAZOLE 143 142 20 2
SINGULAIR 124 119 21 85
METOPROLOL SUCCINATE 120 120 22 14
ALENDRONATE SODIUM 120 118 22 39
SYMBICORT 115 112 24 109
WARFARIN SODIUM 112 105 25 22
CHLORTHALIDONE 112 111 25 274
CLOPIDOGREL 111 106 27 24
PLAVIX 107 102 28 32
CLONIDINE HCL 106 106 29 66
MEGESTROL ACETATE 105 105 R 30 198
SUCRALFATE 100 100 31 221
VESICARE 94 94 32 104
DOXAZOSIN MESYLATE 88 88 33 64
ZOLPIDEM TARTRATE 87 87 34 15
PROAIR HFA 86 80 35 73
LIDODERM 85 76 36 113
PENTOXIFYLLINE 83 75 37 251
GLYBURIDE 75 75 R 38 87
ALLOPURINOL 73 57 39 60
MONTELUKAST SODIUM 73 71 39 189
ACTONEL 71 71 41 207
MECLIZINE HCL 68 65 42 159
DIGOXIN 68 65 42 51
AMLODIPINE BESYLATE-BENAZEPRIL 66 66 44 166
SPIRONOLACTONE 66 66 44 126
KETOCONAZOLE 65 62 46 103
NEXIUM 65 61 46 34
PAROXETINE HCL 63 63 48 84
ADVAIR DISKUS 62 55 49 37
VENTOLIN HFA 58 58 50 123
GEMFIBROZIL 57 45 51 210
NAMENDA 56 56 52 27
METOPROLOL TARTRATE 56 44 52 7
BENAZEPRIL HCL 54 54 54 140
LACTULOSE 53 53 55 254
TAMSULOSIN HCL 52 52 56 11
LANTUS SOLOSTAR 50 37 57 88
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 18, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.